Goldman Sachs Starts Immunomedics (IMMU) at Buy

September 17, 2018 5:15 AM

Goldman Sachs analyst Paul Choi initiates coverage on Immunomedics (NASDAQ: IMMU) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found